Suppr超能文献

12-脱氧佛波醇酯通过激活蛋白激酶 C-δ/蛋白激酶 D/细胞外信号调节激酶信号通路诱导人肺癌 A549 细胞生长停滞和凋亡。

12-Deoxyphorbol Esters Induce Growth Arrest and Apoptosis in Human Lung Cancer A549 Cells Via Activation of PKC-δ/PKD/ERK Signaling Pathway.

机构信息

Graduate Institute of Natural Products, Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Department of Pharmacognosy, Interdisciplinary Excellence Centre, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary.

出版信息

Int J Mol Sci. 2020 Oct 14;21(20):7579. doi: 10.3390/ijms21207579.

Abstract

Prostratin, a non-tumor promoting 12-deoxyphorbol ester, has been reported as a protein kinase C (PKC) activator and is shown to have anti-proliferative activity in certain cancer cell types. Here we show that GRC-2, a prostratin analogue isolated from , is ten-fold more potent than prostratin for inhibiting the growth of human non-small cell lung cancer (NSCLC) A549 cells. Flow cytometry assay revealed that GRC-2 and prostratin inhibited cell cycle progression at the G2/M phase and induced apoptosis. The cytotoxic effect of GRC-2 and prostratin was accompanied by activation and nuclear translocation of PKC-δ and PKD as well as hyperactivation of extracellular signal-related kinase (ERK). Knockdown of either PKC-δ, PKD or ERK significantly protected A549 cancer cells from GRC-2- and prostratin-induced growth arrest as well as apoptosis. Taken together, our results have shown that prostratin and a more potent analogue GRC-2 reduce cell viability in NSCLC A549 cells, at least in part, through activation of the PKC-δ/PKD/ERK pathway, suggesting the potential of prostratin and GRC-2 as anticancer agents.

摘要

普拉司他汀是一种非肿瘤促进的 12-去氧佛波醇酯,已被报道为蛋白激酶 C(PKC)激活剂,并显示在某些癌细胞类型中具有抗增殖活性。在这里,我们表明,从 中分离出的普拉司他汀类似物 GRC-2 比普拉司他汀抑制人非小细胞肺癌(NSCLC)A549 细胞生长的效力高十倍。流式细胞术分析显示,GRC-2 和普拉司他汀抑制细胞周期在 G2/M 期进展,并诱导细胞凋亡。GRC-2 和普拉司他汀的细胞毒性作用伴随着 PKC-δ 和 PKD 的激活和核转位以及细胞外信号相关激酶(ERK)的超活化。PKC-δ、PKD 或 ERK 的敲低显著保护 A549 癌细胞免受 GRC-2 和普拉司他汀诱导的生长停滞和细胞凋亡。总之,我们的结果表明,普拉司他汀和一种更有效的类似物 GRC-2 通过激活 PKC-δ/PKD/ERK 通路降低 NSCLC A549 细胞的活力,至少部分是通过激活 PKC-δ/PKD/ERK 通路,表明普拉司他汀和 GRC-2 作为抗癌药物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a003/7589005/69942113fb62/ijms-21-07579-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验